🔗 Share this article

Given that America proceeds with unprecedented adjustments to its vaccine guidelines, an unexpected name has surfaced in a surprising turn: Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by expressing skepticism about Covid vaccinations throughout the pandemic and has focused upon possible fatalities after COVID-19 immunization in her recent time at the FDA.

Proposed Changes to Childhood Immunization Program

Agency leaders had intended to announce major revisions to the pediatric immunization program earlier this month, bringing the US with the Danish national calendar, according to reports – a major change that would place the US out of step with many the world with little proof for improved outcomes. The planned update has been delayed until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is listed to speak at the event. She was recently named temporary leader of the FDA’s CDER, the fifth individual to lead the office this calendar year.

Consolidating Power at the Agency

Høeg's temporary position might represent a strengthened alliance between the pharmaceutical and biologics branches as Høeg and Prasad solidify control at the regulatory agency – and it signals a increased emphasis upon dismantling previously authorized immunizations at the FDA.

The new acting director has frequently advocated for halting some childhood shot schedules in the US in order to be more in line with Denmark's approach, a country with comprehensive healthcare and a number of inhabitants about the size of Wisconsin’s.

To date statements, she has persisted in emphasizing on vaccination policy – typically the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Expertise

Dr. Høeg has no obvious experience in drug development, oversight or administrative roles, which has been typical for previous leaders of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for running the drug-regulation department, stated Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in managing a large organization. She is not an expert in pharmaceutical oversight.”

Previous directors of the center would “be deeply familiar with legal statutes and the research of medication creation”, noted Dr. Janet Woodcock. “Objectively, she lacks the sort of resume that previous people who headed CBER have had.”

This division has an vast portfolio at the agency, the former commissioner pointed out.

“Many people just zeroes in on the novel medication approvals, but the generic program authorizes thousands of generic medications. There is also a biosimilars program, OTC medication office and other areas, and every single one must be supervised,” Dr. Woodcock explained. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Furthermore, a major administrative element to the position, which supervises over 5,000 employees. “It’s a huge administrative position, if you perform it correctly,” she added.

Agency Reaction and Contentious Initiatives

In response to inquiries about Dr. Høeg's qualifications and whether this appointment signifies greater collaboration among agency officials on vaccines, a press secretary said that the “questions stem from incorrect presumptions”.

“This background is consistent with the functions of her role,” the representative said, pointing to the months Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

As acting director, Høeg assumes responsibility for the agency head's recently launched expedited review system, a contentious one-day therapy clearance system that apparently worried her former heads. “By what process are these therapies being picked for this expedited pathway? Who takes the decisions?” Dr. Howard asked. “There’s a lot of secrecy going on at the agency right now.”

Broadly speaking, he stated, “the Food and Drug Administration appears to be shifting towards laxer rules of most medications, except for shots.”

Public Track Record on Immunizations

Regarding immunizations, Høeg has a more established, if troubling, history, Howard said. She released a study using unconfirmed public submissions to determine the incidence of heart inflammation following COVID-19 immunization. She advised the Florida top health official Dr. Joseph Ladapo, who was said to have altered data to imply Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the incoming federal leadership encompassed changing guidelines for novel immunizations and ending “optional” vaccines, she stated following the vote on a podcast. At the FDA, Dr. Høeg has reportedly floated the idea of excluding young men from getting Covid vaccinations.

“She is an all-around true believer who commences with her beliefs and tailors the evidence to retrofit the science in a extremely disingenuous, dishonest way,” Howard stated.

Consolidating Power and a “Push for Payback”

Høeg joined other contrarians, {like|